SIM
UTHR icon

SummerHaven Investment Management’s United Therapeutics UTHR Stock Holding History

SummerHaven Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,617
Closed -$649K – 297
2021
Q2 		$649K Buy
3,617
+90
+3% +$17.1K 0.37% 156
2021
Q1 		$590K Hold
3,527
– – 0.36% 167
2020
Q4 		$535K Buy
+3,527
New +$463K 0.41% 158

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummerHaven Investment Management's UTHR Position: Q3 2021 in Review

SummerHaven Investment Management sold out of United Therapeutics (UTHR) in Q3 2021, closing a stake of 3,617 shares — an estimated $649K sold.

SummerHaven Investment Management first reported a position in UTHR in Q4 2020 and held it in 3 quarters. The position peaked at $649K in Q2 2021. 426 funds tracked by Wall St. Rank hold UTHR as of Q3 2021.

  • SummerHaven Investment Management reported no remaining United Therapeutics position as of Q3 2021 after selling out during the quarter.
  • SummerHaven Investment Management sold 3,617 United Therapeutics shares in Q3 2021, an estimated $649K.
  • SummerHaven Investment Management first reported a position in United Therapeutics in Q4 2020 and held it in 3 quarters.
  • SummerHaven Investment Management's United Therapeutics position peaked at $649K in Q2 2021.
  • 426 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2021.

Based on SummerHaven Investment Management's 13F filing for Q3 2021, filed 20 Oct 2021.